Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 6/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | TLR4 | O00206 | 3/20 | 0.46 |
| ▸ | TLR2 | O60603 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30072571 | 1.00 | HSD17B10 (0.52) | HSD17B10ALDH1A1TSHRMAPTMEN1 | |
| SCHEMBL18345260 | 0.91 | HSPB1 (0.46) | HSD17B10ALDH1A1TSHRMAPTMEN1 | |
| SCHEMBL2538774 | 0.88 | TSHR (0.52) | HSD17B10ALDH1A1TSHRMAPTMEN1 | |
| SCHEMBL30970189 | 0.88 | MAPT (0.52) | HSD17B10ALDH1A1TSHRMAPTMEN1 | |
| SCHEMBL2539419 | 0.87 | MAPT (0.56) | HSD17B10ALDH1A1TSHRMAPTMEN1 | |
| SCHEMBL2271210 | 0.87 | SMN1; SMN2 (0.54) | HSD17B10ALDH1A1TSHRMAPTMEN1 | |
| SCHEMBL6180876 | 0.87 | MERTK (0.52) | ALDH1A1TSHRMAPTMEN1KMT2A | |
| SCHEMBL6087961 | 0.86 | MEN1 (0.58) | ALDH1A1MAPTMEN1KMT2AL3MBTL1 | |
| SCHEMBL6567485 | 0.86 | PIN1 (0.52) | HSD17B10ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL2531644 | 0.85 | HSPB1 (0.57) | HSD17B10ALDH1A1TSHRMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3386992-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | Janssen Pharmaceutica, N.V. (BE) | 2018-10-17 | — | — | EP | claimed |
| WO-2017100668-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-15 | — | — | WO | claimed |
| US-20240383914-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2024-11-21 | — | — | US | disclosed |
| EP-4463442-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-118613473-A | Compounds and compositions for treating disorders associated with STING activity | 艾福姆德尤股份有限公司 | 2024-09-06 | — | — | CN | disclosed |
| US-12065446-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | JANSSEN PHARMACEUTICA NV (BE) | 2024-08-20 | — | — | US | disclosed |
| WO-2023249994-A1 | METHODS AND MATERIALS FOR TREATING CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20230271941-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-31 | — | — | US | disclosed |
| US-20230271941-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-31 | — | — | US | disclosed |
| US-20230250060-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230250060-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-5637593-A | MIGRAINE; HYPOTENSIVE AGENTS | SMITHKLINE BEECHAM PLC (GB) | 1997-06-10 | — | — | US | disclosed |
| EP-0674619-A1 | TRYPTAMINE ANALOGUES AS 5-HT 1?-LIKE AGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-10-04 | — | — | EP | disclosed |
| WO-1995021815-A1 | CYCLOBUTANE DERIVATIVES AND THEIR USE AS INHIBITORS OF PROTEIN FARNESYLTRANSFERASE AND SQUALENE SYNTHASE | ABBOTT LABORATORIES (US) | 1995-08-17 | — | — | WO | disclosed |
| WO-1994014770-A1 | TRYPTAMINE ANALOGUES AS 5-HT1-LIKE AGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-07-07 | — | — | WO | disclosed |
| EP-0415641-A1 | Substituted glutaramic acids and derivatives | ROHM AND HAAS COMPANY (US) | 1991-03-06 | — | — | EP | disclosed |
| EP-0415642-A1 | Glutarimides | ROHM AND HAAS COMPANY (US) | 1991-03-06 | — | — | EP | disclosed |
| US-4619689-A | Diphenyl ether derivatives and herbicides containing same | MITSUI TOATSU CHEMICALS, INC. (JP) | 1986-10-28 | — | — | US | disclosed |
| US-4566897-A | Diphenyl ether derivatives and herbicides containing same | MITSUI TOATSU CHEMICALS, INC. (JP) | 1986-01-28 | — | — | US | disclosed |
| US-4515628-A | PRE- AND POSTEMERGENCE | MITSUI TOATSU CHEMICALS, INC. (JP) | 1985-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12065446-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | ABL1, BTK, LYN | HSD17B10 3357/4885ALDH1A1 4036/4885TSHR 3846/4885 |
| US-20240383914-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | ABL1, BTK, MYLK2 | HSD17B10 3397/4885ALDH1A1 3938/4885TSHR 4089/4885 |
| US-20230271941-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | HSD17B10 4346/4885ALDH1A1 4654/4885TSHR 4487/4885 |
| US-20230250060-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | HSD17B10 4346/4885ALDH1A1 4654/4885TSHR 4487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.